RTN4 and myeloid sarcoma: Nogo-A has been an attractive target in MS research, whereby a therapeutic passively transferred antibody, targeting Nogo-A during the course of EAE in mice, can reduce the incidence, severity and pathological sequelae, by limiting axonal damage [47].